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Abstract 
Introduction  
The Comprehensive in vitro Proarrhythmic assay (CiPA) aims to update current cardiac 
safety testing to better evaluate arrhythmic risk. A central theme of CiPA is the use of in 
silico approaches to risk prediction incorporating models of drug binding to hERG. To 
parameterize these models, accurate in vitro measurement of potency and kinetics of block is 
required. The Ion Channel Working Group was tasked with: i) selecting a protocol that could 
measure kinetics of block and was easily implementable on automated platforms for future 
rollout in industry and ii) acquiring a reference dataset using the standardized protocol. 
Methods  
Data were acquired using a ‘step depolarisation’ protocol using manual patch-clamp at 
ambient temperature. 
Results 
Potency, kinetics and trapping characteristics of hERG block for the CiPA training panel of 
twelve drugs were measured.  Timecourse of block and trapping characteristics could be 
reliably measured if the time constant for onset of block was between ~500 ms and ~15 sec. 
Seven drugs, however had time courses of block faster than this cut-off.  
Discussion 
Here we describe the implementation of the standardized protocol for measurement of 
kinetics and potency of hERG block for CiPA.  The results highlight the challenges in 
identifying a single protocol to measure hERG block over a range of kinetics. The dataset 
from this study is being used by the In Silico Working Group to develop models of drug 
binding for risk prediction and is freely available as a ‘gold standard’ ambient temperature 
dataset to evaluate variability across high throughput platforms.  
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1. Introduction 
 
Acquired, or drug-induced, long QT syndrome (aLQTS) occurs most often as a result of 
pharmacological block of hERG (human ether-a-go-go related gene)/Kv11.1 potassium 
channels in the heart. Reduced hERG function prolongs the QT interval on the surface 
electrocardiogram and increases the risk of the potentially fatal cardiac arrhythmia torsade de 
pointes (TdP) (Roden, 2004). Over the past twenty years a range of structurally unrelated 
cardiac and non-cardiac drugs have been withdrawn from market as a result of these side 
effects (Shah, 2008). The introduction, in 2005, of a series of mandated tests (ICH S7B and 
E14) for all new drugs to assess hERG block, cardiac action potential prolongation and QT 
interval prolongation has meant that no new drugs have been removed from market due to 
unacceptable Torsadogenic risk in the last decade.  
 
However, eliminating hERG blocking properties from drugs in development is a difficult task 
since it has been estimated that between 70 and 86% of compounds block hERG at some 
concentration (Shah, 2008). Furthermore, there is growing concern that whilst current tests 
are very sensitive, they are not specific, meaning potentially safe drugs are having their 
development prematurely terminated (Fermini et al., 2016; Gintant et al., 2016; Sager et al., 
2014). For example, verapamil has been prescribed to millions of patients worldwide over 40 
years with no incidence of TdP despite blocking hERG in its therapeutic range. This apparent 
anomaly can be explained by verapamil’s multichannel pharmacological profile whereby in 
addition to hERG, it also blocks calcium channels, so ameliorating risk by eliminating early 
after depolarisation (EAD) triggers for initiation of arrhythmia (Aiba et al., 2005). However, 
under current preclinical guidelines based on block of hERG channels, verapamil would 
never have been developed as a therapeutic. It should be noted however, that while it is 
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impossible to know how many ‘safe’ compounds in preclinical development have had their 
development terminated based on positive hERG hits, there are relatively few example of on-
market drugs (such as verapamil) where this is the case. Nevertheless, issues such as this 
have prompted a rethink of how drugs should be tested and have led to the recent proposal of 
the Comprehensive in vitro Proarrhythmic Assay (CiPA) (Fermini et al., 2016; Gintant et al., 
2016; Sager et al., 2014). CiPA aims to develop new mechanism based testing that employs 
actual markers of proarrhythmic propensity as opposed to the relatively poor surrogates 
(hERG block, AP prolongation) that are currently used to predict this risk. One of the 
proposed streams of CiPA is the use of in silico models of human cardiac electrophysiology 
incorporating temperature-dependent models of hERG gating (Li et al., 2016) as well as 
descriptions of drug binding to hERG (and potentially other ion channels), including the 
kinetics of drug interactions. This approach will allow integration of how drugs with 
potentially complex state dependent binding kinetics interact with the hERG channel in a 
dynamic manner during the cardiac action potential to modify repolarisation and risk. 
 
The goal in regard to the practical implementation of the in silico aspect of CiPA is that a 
selected voltage-clamp protocol will be run as part of preclinical development to measure 
drug binding kinetics to hERG. The data from this protocol will be used to constrain 
standardized in silico models of drug binding to hERG to predict proarrhythmic risk when 
incorporated into human action potential simulations. To achieve this, the protocol should 
ideally be able to measure both potency and kinetics of drug binding to hERG and be 
amenable to data acquisition in the high throughput automated patch clamp systems that are 
currently employed within industry. To this end, the Ion Channel Working Group (ICWG) 
and In Silico Working Groups (ISWG) identified the step depolarisation protocol described 
by Milnes et al. (Milnes et al., 2010) as a suitable protocol for testing (see Colatsky et al., 
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2016 for details on the motivation and makeup of the individual working groups within 
CiPA). 
 
In this study we present the ‘gold standard’ CiPA dataset describing block of hERG channels 
by a training panel of 12 drugs, split equally between low, medium and high risk (Colatsky et 
al., 2016). The data was acquired using manual patch clamp to provide the highest fidelity of 
recordings and accuracy of measurement against which other automated high throughout 
approaches can be measured (Hancox et al., 2008). Data was gathered at ambient temperature 
since this is most relevant to most high throughput platforms on which the assay will be run. 
In addition to potency of block, we measured the kinetics of onset of block and the extent of 
drug trapping (the degree to which a drug is able to dissociate from the closed state) using the 
step depolarisation protocol (Milnes et al., 2010). We observed a much wider variety of 
kinetics of drug binding than expected. For drugs with kinetics of block that were very slow, 
we had to extend the duration of the protocol to enable estimation of kinetics of block. 
Furthermore, we also found that for about half of the drugs tested, the onset of block was at 
least as fast as the rate of channel activation and so it was not possible to measure the kinetics 
of binding using the step depolarisation protocol under the recording conditions used in this 
study. The dataset gathered as part of this study is being used by the In Silico Working Group 
to develop models of drug binding for risk prediction, to evaluate the temperature 
dependence of drug binding to hERG and is freely available as a ‘gold standard’ ambient 
temperature dataset to evaluate variability in automated patch clamp platforms.  
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2. Materials and methods 
 
2.1 Cell culture 
CHO cells stably expressing hERG/Kv11.1 were purchased from the American Type Culture 
Collection (ATCC reference PTA-6812). Cells were cultured in Hams F12 nutrient mix 
(ThermoFisher Scientific, Waltham, USA) containing 5% fetal bovine serum (Sigma-
Aldrich, Sydney, Australia) and maintained at 37 ⁰C with 5% CO2. 
 
2.2 Patch clamp 
Whole cell patch clamp currents were evoked from CHO cells in the voltage clamp 
configuration at 22⁰C. The current signal was amplified and filtered at 1 kHz with an 
Axopatch 200B (Molecular Devices, Sunnyvale, USA) and sampled at 5 kHz with a PC 
interfaced with an analog to digital converter, Digidata1440A (Molecular Devices). Series 
resistance compensation was >80%. Leak currents were subtracted manually offline. Data 
was acquired with pCLAMP 10 (Molecular Devices) acquisition software and analysed using 
Clampfit (Molecular Devices) and Prism (v6, GraphPad, San Diego, USA). 
 
Single use patch pipettes were pulled from borosilicate glass (Harvard Apparatus, Holliston, 
USA) with resistances of 2-5 MΩ. Pipettes were filled with internal solution containing (in 
mM): 120 potassium gluconate, 20 KCl, 1.5 Mg2ATP, 5 EGTA and 10 HEPES, adjusted to 
pH 7.2 with KOH. The external bath solution contained (in mM); 130 NaCl, 5 KCl, 1 MgCl2, 
1 CaCl2, 12.5 glucose and 10 HEPES, adjusted to pH 7.4 with NaOH. The calculated liquid 
junction potential of -15 mV (Barry, 1994) was corrected for by adjusting voltage pulse 
protocols prior to stimulation.  For the experiments presented in this paper the whole cell seal 
resistance was 1.6 +/- 0.1 GΩ, access resistance was 4.6 +/- 0.2 MΩ, holding current was -
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21.1 +/- 1.4pA and cell capacitance was 20.5 +/- 0.5 pF (n = 138, mean +/- SE) (see 
Supplementary Figure S1) 
 
2.3 Drug application/Pharmacology 
The CiPA Clinical Translation Working Group (CTWG), an expert team of cardiac 
electrophysiologists, safety pharmacologists and clinicians, selected a panel of 12 drugs split 
equally between low, intermediate and high proarrhythmic risk, on which in vitro testing 
against hERG channels would be centred (Table 1) (Colatsky et al., 2016). The 
concentrations selected for testing were based on previously published data (Antzelevitch et 
al., 2004; Crumb et al., 2016; Gualdani et al., 2015; Redfern et al., 2003), albeit gathered 
under different conditions and protocols. The fold difference from the maximum free plasma 
concentration (Free Cmax) (Crumb et al., 2016) is also listed in Table 1. 
 
The Dynaflow Resolve (Cellectricon, Mölndal, Sweden) microfluidic solution exchange 
system was used to apply drugs (solution exchange time <30 msHill et al., 2014). Where 
necessary for solubility, drugs were dissolved in DMSO. The maximum amount of DMSO 
never exceeded 0.1% (v/v), a concentration which has been shown to have no effect on hERG 
channel activity (Walker et al., 1999).  
 
2.4 Data analysis 
Steady state concentration-response data were fit with the Hill equation: 
                         Eqn 1 
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where [x] is drug concentration, nH is the Hill coefficient (slope parameter), and IC50 is the 
concentration at which 50% block of channel current is evident. For simplicity, the Hill 
curves fit to the concentration response data were constrained to minima of 0 and maxima of 
100 % block. 
 
To measure the kinetics of drug block, the timecourse of the block onset was calculated 
through offline subtraction:                                        Eqn 2 
Where i is the control current trace (no drug) and ii is the first trace in the presence of drug. 
The percentage block data was fitted with a standard exponential function yielding a single 
time constant (τon):                                 Eqn 3 
Where Im is the maximum percentage block at t = 0, Id is the percentage block plateau 
amplitude in the presence of drug, t is time, τon is the time constant. 
 
2.5 Chemical compounds 
All chemicals were supplied by Sigma-Aldrich (Sydney, Australia) unless otherwise stated. 
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3. Results 
3.1 Protocol implementation 
The step depolarisation protocol from Milnes et al. (Milnes et al., 2010) was chosen by the 
ICWG and ISWG as the standard protocol for gathering data describing kinetics of drug 
binding to hERG for CiPA (Figure 1). The basic protocol unit has a 25 s start-to-start time 
including a 10 s depolarizing step to 0mV with a 15 s interpulse interval at a holding potential 
of -80 mV (Figure 1Ai). For data acquisition, the protocol was run in three phases (Figure 1). 
Initially the 0 mV 10s voltage pulse was repeated 5 times in the absence of drug to ensure 
currents were stable and to obtain control current profiles (sweeps 1-5, Figure 1Ai). 
Following this a further 5 sweeps, without the depolarizing step, where the cell membrane 
was held at -80 mV for 25s each (total 125 s) were acquired while the drug is washed into the 
system (sweeps 6-10, Figure 1Aii) with the channel closed. Finally, a third phase of five 
sweeps of the basic protocol including the depolarizing step to 0 mV were acquired, in the 
continued presence of drug during which the onset of block is visible as the reduction in the 
hERG current over the duration of the 10 s depolarizing step (sweeps 11-15, Figure 1Aiii). In 
this example, the drug block reached equilibrium within the first sweep, meaning subsequent 
current traces are directly overlaid. The percentage of drug block measured at the end of the 
5th drug sweep (sweep 15, Figure 1Aiii) was used to measure the potency of the drug and to 
plot concentration response curves (see for example Figure 3). 
 
To measure the kinetics of the onset of drug block the hERG currents were subtracted offline 
and fit with exponential curves. Specifically, the first hERG current trace recorded in 
response to the 0 mV voltage step in the presence of drug (sweep 11, (ii) Figure 1B, left) was 
subtracted from the last hERG trace before drug was perfused (sweep 5, (i) Figure 1B, left). 
The percentage block over time was then calculated by dividing the subtracted trace by the 
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last control trace (sweep 5) and multiplying by 100 (Figure 1B, right). An exponential 
function was fit to the percentage block data to give a single time constant representing the 
timecourse of drug block (see Materials and Methods). 
 
3.2 Potency of hERG block 
All of the drugs tested, with the exception of dofetilide, had at least one concentration that 
reached steady state block within or close to the end of the first 10 s voltage pulse. 
Representative raw hERG current traces recorded in response to ~IC50 concentrations, for 
those drugs where the 10 s pulse was sufficient for all 3 concentrations tested to reach steady 
state are shown in Figure 2. The concentration response curves for all 12 drugs are plotted in 
figure 3. The IC50values, together with a comparison to previously published data, are listed 
in Table 2. 
 
3.3 Kinetics of hERG block 
Measured time constants for the onset of drug block (τon) for the eleven drugs where the 
timecourse of block could be reliably measured for at least one concentration using the 
standard 10 s protocol are shown in Figure 4. For some drugs (cisapride and verapamil), a 
clear concentration dependence for the timecourse of block onset is observed using this initial 
implementation of the protocol. For example, τon was measured as 5.6 ± 0.6 s, 3.1 ± 0.3 s and 
1.9 ± 0.2 s for 100, 300 and 1000 nM verapamil, respectively. However, for those drugs with 
faster kinetics (quinidine, sotalol, chlorpromazine, diltiazem, mexiletine, onsansetron and 
ranolazine), no concentration dependence of the time course of onset of block was apparent 
but rather some block appeared as an instantaneous effect that was present as soon as the 
channel opened. We considered that this could potentially be explained by one of two 
reasons: first, for these drugs the onset of block was faster than the rate of hERG channel 
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activation at 0 mV and therefore could not be accurately resolved using this protocol; or 
second, that the drug was able to block the channel in the closed state during the drug 
equilibration period at -80 mV (sweeps 6-10, Figure 1Aii). To address this question we used 
the Dynaflow resolve microfluidic solution exchange system (Cellectricon, Sweden) to 
directly measure the timecourse of onset of block at 0 mV for a subset of the drug panel. A 
typical example showing block and washoff profiles for 10, 30 and 100 μM diltiazem is 
shown in Figure 5B. To analyse data gathered using this protocol, an exponential function 
was directly fitted to the timecourse of current decay during application of drug to measure 
the timecourse of block (Figure 5D) (Hill et al., 2014). In contrast to the step depolarisation 
protocol, a clear concentration dependence of the timecourse for onset of block for fast drugs 
could be resolved using this approach with τon values measured as 299 ± 42, 204 ± 38 and 
114 ± 34 ms for 10, 30 and 100 μM diltiazem respectively (mean ± SE, n = 4-5, Figure 5E). 
Similar results were observed for other fast drugs tested (ranolazine and mexiletine, 
Supplementary Figure 3) providing evidence that these drugs do block as fast, or faster than 
the rate of channel opening at 0 mV hence the inability to obtain accurate measurements of 
the timecourse of the onset of block using the step depolarisation protocol. 
 
A second limitation of the initial implementation of the protocol (that incorporated the 10 s 
depolarizing step) was the inability to measure kinetics of block for those drugs where the 
timecourse of the onset of block was very slow. Specifically, low concentrations of cisapride, 
bepridil and terfenadine as well as all concentrations of dofetilide did not reach steady state 
block within the 10 s time period (Figure 6A) and yielded highly variable results when fit 
with an exponential curve. To examine this in more detail, we analysed the measured 
timecourse of the onset of block for 30 nM cisapride as a function of the duration of the 
depolarizing pulse (Figure 6B). While no reliable fit could be obtained with a 10 s 
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depolarizing step, we saw a large standard error when measurements were made with a 20 s 
step (206 ± 393 s), that was reduced with a 30 s step (31 ± 14 s) and even further at 40 s (26 ± 
7 s). As a rule, the step should be 2-3 times the time constant to obtain a consistent 
measurement. Similar results were seen for other slow drugs (data not shown) and 
subsequently a modified protocol incorporating a longer 40 s 0mV pulse protocol was 
introduced for the subset of drugs where 10 s was not sufficient to measure onset of block.  
Representative traces for each of the 4 drugs used with the 40 s protocol are shown in Figure 
6C. While 3 of the 4 drugs reached close to steady state block within the 40 s duration it is 
evident that for 10 nM dofetilide the length of the protocol was still not sufficient for steady-
state inhibition to occur, reaching only 20.7 ± 1.8 % of the final 68.6 ± 8.3% block within the 
first 40 s sweep (n = 4). The variability in the measured onset of block for 10 nM dofetilide is 
clearly evident in Figure 6D and kinetic data for 3 nM dofetilide is absent as the degree of 
block was negligible in the first 40 s sweep. The other τon values obtained from 40s 0 mV 
pulses are shown in Figure 6D and combined with other 10 s 0 mV data obtained with the 
same drugs to further demonstrate the concentration dependency of the block kinetics (see 
supplementary figure 2 and table 1 for a summary kinetic data for entire drug panel). 
 
 3.4 Drug trapping 
Another parameter that can be approximated to some degree from this dataset, and may be 
important in characterising the nature of drug/hERG interactions, was the degree of drug 
trapping. Trapping refers to the phenomenon that upon closing of a drug-bound channel in 
response to membrane repolarisation, a drug might be unable to dissociate from the closed 
state as it is ‘trapped’ in the channel pore (Mitcheson et al., 2000). As a result of this, upon 
subsequent depolarisation of the membrane and accompanying activation of the hERG 
channel, a proportion of the population remains drug bound, depending on the degree of 
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trapping that has occurred. To determine the extent of drug trapping, we estimated the 
percentage channel block at the start of the 5th sweep in the presence of drug (sweep 15), as 
illustrated in Figure 7A. Sweep 15 was fitted with an exponential curve, excluding the first 
0.5 s due to the high degree of noise, and this fit was extrapolated back to t = 0. The degree of 
block at time point 0 was then expressed as a percentage of the block at the end of the 10 or 
40 s depolarization step for sweep 15. In the example illustrated in Figure 7A, the extent of 
block at the start of the 15th sweep was 73% of the block observed at the end of the 15th 
sweep (see supplementary figure 4 for a summary of trapping for sweeps 12 to 15). The 
highest concentration of drug tested was used to do this calculation and due to the noise 
within the first 0.5 s of the trace only drugs with τon values >500 ms resulted in meaningful 
measurements. The degree of trapping measured was >90% for two drugs, dofetilide, and 
terfenadine (98.1, 97.3 and trapped respectively, Figure 7B). In comparison, bepridil and 
cisapride were 78.7% and 64.7% trapped while verapamil block was almost completely 
relieved at the beginning of each sweep (only 17.8% trapped). 
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4. Discussion 
In this study we present the ‘gold standard’ manual patch clamp dataset describing hERG 
channel block at ambient temperature for the CiPA training panel of twelve drugs. Using a 
‘step depolarisation’ protocol modified from Milnes et al. (Milnes et al., 2010) we measured 
potency, kinetics of onset of block and drug trapping –features that are anticipated will be 
employed in developing in silico models for pro-arrhythmia risk prediction as part of CiPA. 
Our data showed that for slow drugs, a modification of the initial implementation of the 
protocol was needed to accurately measure kinetics, while for drugs whose onset of block 
occurred faster than the rate of channel activation at 0 mV, timecourse of block development 
could not be fully resolved across all concentrations using this protocol. The methodology 
described here provides a blueprint for implementation in industry, while the dataset (all raw 
data openly available along with this publication) serves as a benchmark for assessing 
variability of future datasets gathered using high throughput automated patch clamp systems, 
operated at room temperature. 
 
4.1 Protocol selection 
Selection of the voltage protocol by the ICWG was based on the requirement to characterise 
both potency and kinetics of hERG channel block such that the data could be used to 
constrain models of hERG/drug interaction for use in in silico pro-arrhythmia risk prediction 
(Fermini et al., 2016). Furthermore, the protocol needed to be amenable to implementation in 
current high throughput automated patch clamp systems, as these are the systems on which 
the protocol will be run in future drug screening pipelines. The ‘step depolarisation’ protocol 
from Milnes et al (Milnes et al., 2010) was chosen as a suitable candidate to meet these 
requirements. The initial implementation of the protocol consisted of three phases: control 
(Figure 1Ai), drug equilibration (Figure 1Aii) and onset of drug block (Figure 1Aiii). The 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
rationale of the equilibration phase, during which the membrane potential is held at -80 mV 
throughout, is that drugs cannot block the channel in the closed state since they cannot reach 
the binding site located in the pore cavity between the selectivity filter and the cytoplasmic 
gate (Carmeliet, 1992; Mitcheson et al., 2000; Spector et al., 1996). This phase therefore 
allows the drug to wash into the system, taking into account solution exchange times as well 
as equilibration of drug into the cytosol of the cell, without blocking the channel. This 
ensures that the timecourse measured in the ‘drug block’ phase reflects only the kinetics of 
the drug/channel interaction, and not properties of the recording system. In this 
implementation of the protocol, each phase consisted of five sweeps, based on the original 
description in Milnes et al (Milnes et al., 2010).  This approach allowed enough control 
sweeps to assess stability of the recording, as well as sufficient time for equilibration of drug. 
However, it is conceivable that for systems with slow solution exchange times for example, 
more repetitions of the individual phases may be required for equilibration. 
 
4.1.1 Drugs with slow binding kinetics 
The initial implementation of the protocol, incorporating a 10 s 0mV step (as originally 
described in Milnes et al., 2010) was too short to accurately measure the timecourse of the 
onset of block during a single protocol application for at least one concentration of four of the 
drugs tested (bepridil, cisapride, terfenadine, dofetilide). As a consequence, we adjusted the 
protocol to increase the duration of the 0 mV step to 40 s, for slow binding drugs. This 
modification enabled the accurate measurement of all concentrations of each of the slower 
blocking drugs, with the exception of dofetilide. For 100 nM dofetilide the degree of block 
only reached 77% by the end of the first 40 s sweep compared to a final equilibrated block of 
97 %. Furthermore, block by 10 nM dofetilide was highly variable and 3 nM dofetilide was 
indistinguishable from control currents. Based on these observations, we suggest that the step 
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depolarisation should be run in two stages when employed at room temperature: stage 1, with 
a 10 s depolarizing step, to assess the broad range of kinetics of the compound being tested; 
stage 2 (if deemed necessary due to slow kinetics identified in Stage 1) with a 40 s 
depolarizing step to accurately measure the timecourse of the onset of block.  
In previous publications using the step depolarisation protocol at physiological 
temperature, the onset of block for dofetilide could be accurately measured within the 
timeframe of the 10 s depolarizing step (on = 3 s for 60 nM dofetilide (Milnes et al., 2010). 
These results suggest that, at least for dofetilide, the kinetics of block are very temperature 
sensitive. This could have important implications for the CiPA initiative in terms of 
determining what temperature the step depolarisation protocol must be run at to acquire data 
that will be useful for constraining in silico models that will be used for simulations at 
physiological temperatures. In this regard, the CiPA High Throughput Stream (HTS), 
sponsored by the Health and Environmental Sciences institute (HESI), is about to embark on 
a large scale study using the step depolarisation protocol. As part of this study, data will be 
gathered describing kinetics and potency of hERG block using the step depolarisation 
protocol over multiple sites and platforms (including Patchliner, QPatch, CytoPatch, IonFlux 
and SyncroPatch) to assess the degree of data variability relative to the gold standard 
presented here. In addition, those sites with the capability will acquire data using the same 
platform at both ambient and physiological temperature in order to assess temperature 
dependence of kinetics and potency of hERG block using the step depolarisation protocol. 
 
4.1.2 Drugs with fast binding kinetics 
For over half of the drugs tested (ondansetron, ranolazine, sotalol, mexiletine, chlopromazine, 
quinidine, diltiazem), the onset of block was too fast to measure using the step depolarisation 
protocol, but rather appeared to be instantaneous. In these cases, the true rate of block is as 
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fast, or faster than hERG activation at 0 mV (560 - 947 ms, Schuster et al., 2011; Vandenberg 
et al., 2006; Zhou et al., 1998). This manifests as an apparent lack of concentration 
dependence to the timecourse of block since the time constant value measured (300 ms on 
average for all 7 drugs, see supplementary table 1 for values) does not actually reflect drug 
binding, but rather the rate limiting step is the rate of activation at 0 mV. Our measurement of 
the timecourse of block of the open channel, following ultrafast microfluidic exchange (Hill 
et al., 2014; Windley et al., 2016), are consistent with time constants of drug block that are 
indeed much faster than the rate of activation at 0 mV. The timecourse of block measured in 
this manner was also concentration dependent, contrary to the data obtained with the step 
depolarisation protocol. Both of these observations support the interpretation that the rate of 
channel opening is the limiting factor in measurement of the timecourse of block for fast 
drugs when using the step depolarisation protocol (Milnes et al., 2010) at ambient 
temperature. We suggest that this limitation will also be the case for any protocol that 
requires pre-incubation of drug prior to measuring the onset of block as the channel activates. 
For drugs in this ‘fast’ category, block may simply have to be approximated as instantaneous 
when incorporated into in silico models for proarrhythmic risk prediction. It should be noted 
however, that while the direct application approach was informative in this context, it is not 
amenable to high-throughput testing since many current automated patch clamp systems do 
not have the capacity for such fast (<30 ms, Hill et al., 2014) solution switching.  
 
4.1.3 Drug trapping 
Using the step depolarisation protocol we were also able to obtain basic data on the relative 
degree of trapping observed for different drugs. Drug trapping occurs when drug does not 
fully dissociate from the channel following repolarisation (Mitcheson et al., 2000). In this 
study the degree of trapping was measured as the proportion of the channel population that 
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remains drug bound between depolarizing steps (see Figure 7). However, using this dataset, it 
is not possible to determine to what degree this ‘trapping’ occurs as a result closure of the 
cytoplasmic gate to prevent diffusion of the drug molecule from the channel vestibule 
(Mitcheson et al., 2000), slow dissociation from a high affinity open/inactivated state block 
or both (Lee et al., 2016; Witchel et al., 2004). It should also be noted that this measure of 
trapping is a snapshot imposed by the fixed 15 s interval at -80 mV between each 
depolarizing step. As a result, no information on the timecourse of recovery from trapping 
can be inferred below this threshold. For example, a drug that completely dissociated within 
5 s could not be distinguished from one that dissociated in 15 s – they would both be 
classified as not trapped. Likewise, given a longer interval, drugs that remain trapped at 15 s 
may further dissociate. However, in the context of creating a model appropriate for the 
physiological conditions of the human heart, where a long beat-to-beat interval might be 2 s, 
such extreme periods at hyperpolarized membrane potentials are unlikely to occur.  
 
Using this approach, the degree of trapping was measured as 18 %, 65 %, 79%, 97 % and 98 
% for verapamil, cisapride, bepridil, terfenadine and dofetilide (Figure 7B). For ‘fast’ drugs 
(see section 4.1.2 above) we did not attempt to measure the degree of trapping since these 
compounds block effectively instantaneously, meaning steady state block is reached at the 
beginning of every sweep, regardless of whether trapping has occurred or not. The degree of 
trapping has previously been suggested to be associated with proarrhythmic risk (Di Veroli et 
al., 2014), so it is interesting to note that all of the high-risk drugs that were tested showed a 
high degree of trapping. In this regard, this measure is being currently evaluated by the ISWG 
(Colatsky et al., 2016) as a biophysical metric that may aid with in silico pro-arrhythmia risk 
prediction. 
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4.2 Comparison to Existing data  
In general, the IC50 values for the twelve drugs, measured using the step depolarisation 
protocol corresponded well to those published within the literature. The observed 
discrepancies, where IC50s were outside of the range of published IC50 values 
(chlorpromazine, bepridil and ranolazine, table 2), can likely be explained by the notable 
protocol dependency of hERG channel block (Kirsch et al., 2004; Milnes et al., 2010; Yao et 
al., 2005). In regards to the timecourse of block, this is the first study to comprehensively 
assess drug binding kinetics for a diverse panel of drugs. Furthermore, only a few studies 
have directly measured the onset of block using the step depolarisation protocol described in 
this study, so limiting direct comparison. However, what information is available shows that 
the measured timecourse of block, like potency, is also very dependent on the protocol used 
to gather the data. For 10 nM cisapride for example, on has been reported between 383 ms 
(Walker et al., 1999) and 26 s (Windley et al., 2016) compared to 42 s reported here. This 
variation demonstrates the importance of using a standardized protocol, such as that 
described here, to ensure consistency in the data describing the kinetics of hERG block that 
will be used to constrain the models to be used for in silico pro-arrhythmia risk prediction. 
An important next step will be to assess whether kinetics and potency measured for drug 
interactions with hERG 1a translate to IKr.  While it might not be possible to acquire this 
dataset from native IKr in human cardiomyocytes, co-expression studies with hERG 1b and/or 
beta subunits in heterologous expression systems may go some way to answering this 
question. 
 
4.3 Limitations.  
One limitation of the protocol detailed in this study is the inability to measure the timecourse 
of drug washout. In principle, off rates for a simple bimolecular interaction can be calculated 
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from measurement of apparent on rates at multiple concentrations. However, this could be 
complicated by the complexities of state dependent drug binding (Ficker et al., 1998; Perrin 
et al., 2008) as well as the subtleties of the trapping phenomenon discussed above. It 
therefore remains to be seen how in silico approaches could overcome this issue. Secondly, 
the issue of temperature effects on kinetics of drug binding need to be considered. While this 
dataset is a benchmark for data gathered by most high throughput patch camp systems 
operating at ambient temperatures, more systems are now able to operate at physiological or 
near physiological temperatures (Obergrussberger et al., 2015; Stoelzle et al., 2011). Both 
potency (Kirsch et al., 2004; Yao et al., 2005) and kinetics (Windley et al., 2016) of block 
have previously been shown to be temperature dependent. Managing these datasets acquired 
at diverse temperatures, and incorporating these temperature effects into in silico models will 
be an important short term focus for the field. 
 
5. Conclusions 
In this study, we describe the standardized implementation of the ‘step depolarisation’ 
protocol (Milnes et al, 2010) selected by the ICWG for measurement of kinetics and potency 
of hERG block for CiPA. The dataset assembled is the most comprehensive study of the 
kinetics of drug binding to hERG assembled to date and is freely available as the reference 
ambient temperature dataset to assess the variability in data acquired across high throughout 
automated platforms in industry. The dataset is currently being used by the in silico working 
group, together with parallel datasets acquired at physiological temperature, to develop in 
silico models of drug binding for use in risk prediction. This effort to accurately measure the 
kinetics of drug binding to hERG is motivated by the reasoning that this knowledge will help 
more accurately determine the risk profile of individual drugs. In a seminal paper, Campbell. 
(Campbell, 1983) subclassified Class I antiarrhythmics based on their kinetics and showed 
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this had practical consequences in determining refractoriness. Similarly, the kinetics of drugs 
interaction with hERG relative to both the kinetics of channel gating as well as the duration 
of the diastolic interval have been shown to be important in determining the degree of action 
potential prolongation and the emergence of proarrhythmic markers (Lee et al., 2016). 
Indeed, it may eventuate that the grouping of hERG blocking drugs based on their kinetics 
may have some utility in future classification. The data presented in this study will provide 
the foundation to asses to what extent knowledge of drug binding kinetics can enhance our 
ability to assign risk, particularly through in silico approaches. We anticipate that further 
studies, extending the data to hERG 1a/1b expression and/or native IKr as well as 
investigating the effects of temperature will help further enhance the efficacy of these models 
in predicting risk. 
 
 
Tables 
Table 1: List of compounds, risk profile, and concentrations tested  
Drug Risk 
Conc 1 (nM)/Fold 
free C
max
 
Conc 2 (nM)/Fold 
free  C
max
 
Conc 3 (nM)/Fold 
free C
max
 
bepridil High 10 / 0.3X 30 / 1X 100 / 3X 
dofetilide High 3 / 1.5X 10 / 5X 100 / 50X 
quinidine High 100 / 0.1X 300 / 0.3X 1000 / 1X 
sotalol High 30000 / 2X 100000 / 7X 300000 / 20X 
chlorpromazine Intermediate 100 / 3X 300 / 9X 1000 / 30X 
cisapride Intermediate 10 / 4X 30 / 12X 100 / 40X 
ondansetron Intermediate 300 / 1X 1000 / 3X 3000 / 10X 
terfenadine Intermediate 10 / 35X 100 / 350X 1000 / 3500X 
diltiazem Low 10000 / 100X 30000 / 300X 100000 / 1000X 
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mexiletine Low 10000 / 4X 30000 / 12X 100000 / 40X 
ranolazine Low 10000 / 5X 30000 / 15X 100000 / 50X 
verapamil Low 100 / 2X 300 / 6X 1000 / 20X 
 
Table 2: Comparison of IC50 values to the literature. (Data obtained from Crumb et al., 2016; 
Hishigaki & Kuhara, 2011; Kirsch et al., 2004; Kramer et al., 2013; Redfern et al., 2003,  a, b, c, d 
and e, respectively) 
 
  
Drug 
     
IC50 (μM) 
IC 50 
95% CI Hillslope 
Hillslope  
95% CI 
IC50 comparison (μM) IC50/Cmax 
Literature 
IC50/Cmax 
(min – max) 
bepridil 0.013 0.0096 – 0.017 1.1 0.7 – 1.6 0.023-0.149 a, b, c, d, e
 
0.4 0.7 – 55.7 
dofetilide 0.0058 0.0044 – 0.0076 1.4 0.8 – 2.0 0.001-0.030 a, b, d, e 2.7 0.5 – 14.0 
quinidine 0.235 0.202 – 0.274 1.3 1.0 – 1.5 0.3-1.1 a, b, c, d, e
 
0.3 0.4 – 1.3 
sotalol 393 300 – 515 1.2 0.8 – 1.5 74-810 a, c, d, e
 
26.8 5.0 – 55.1 
chlorpromazine 0.1663 0.146 – 0.190 1.4 1.1 -1.7 1.1-1.5 a, d
 
4.8 31.9 – 43.5 
cisapride 0.0189 0.014 – 0.026 0.9 0.6 – 1.2 0.002-0.045 a, b, c, d, e
 
7.3 0.8 – 17.5 
ondansetron 1.028 0.782 – 1.35 0.9 0.6 – 1.2 0.081-1.5 a, b
 
2.9 0.2 – 4.2 
 
terfenadine 0.0131 0.012 – 0.014 1.0 0.9 – 1.1 0.0066-0.204 a, b, c, d, e
 
45.8 23.1 – 712.7 
diltiazem 12.8 109  – 150 1.0 0.9 – 1.2 6.5-53.2 a, d, e
 
5981 3037 – 24 858 
mexiletine 104.7 64.9 – 169 0.8 0.4 – 1.2 N/A 41.8 N/A 
ranolazine 35.7 28.1 – 45.4 1.0 0.7 – 1.3 6.4-12 a, e
 
18.3 3.3 – 6.2 
verapamil 0.3995 0.350 – 0.456 1.0 0.9 – 1.2 0.136-0.499 a, b, c, d, e
 
8.9 3.0 – 11.1 
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Figure legends 
Figure 1: Depolarizing step protocol implementation. (A) hERG currents were recorded 
from CHO cells using whole cell patch clamp. Each experiment was divided into three 
phases: hERG currents were recorded in the absence of drug (i), drug was then applied to the 
closed channel at -80 mV (ii) and finally hERG currents were recorded in the presence of 
drug (iii). The timecourse of hERG block onset was assessed by using the offline subtraction 
routine illustrated in (B). Overlaid traces represent the last control sweep (I, black), the first 
hERG current response in the presence of drug (II, red) and the subtracted current (II-I, grey). 
The inset demonstrates the subtraction as a percentage of the control current (black) and the 
fitting of an exponential function to the data to calculate a time constant (τ) corresponding to 
the timecourse of block.  
 
Figure 2: Representative leak corrected raw hERG data traces in response 10 s 0 mV voltage 
steps from a holding potential of -80 mV. The overlaid traces represent control (sweep 5, 
grey), the onset of drug block (sweep 11, coloured) and steady state block (sweeps 12-15).  
 
Figure 3: Concentration response data for the CiPA training panel of 12 drugs. 3-4 
concentrations were tested for each drug and data represents the mean ± SE of 4-5 cells. The 
percentage block was calculated from the current measured at the end of the 5th 0mV sweep 
in response to drug and expressed as a percentage of the current at the same time point of the 
last control sweep. Data was fit by Hill equation with the maxima and minima constrained to 
100 and 0% respectively 
 
Figure 4: Kinetics of hERG drug block. Plots represent the time constants for the onset of 
block (on) for all drug concentrations where responses were successfully fit with an 
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exponential function. hERG currents were evoked by a 10s 0 mV voltage step from a holding 
potential -80mV. Data represents mean (black line) ± SE for n = 4-5, overlaid with the 
individual data points. Concentrations where the degree of block was too small to measure 
the timecourse of block accurately are marked (#). 
 
Figure 5: Drugs where onset of block is too fast to accurately measure. (A) Shows a 
representative hERG trace where the onset of current was similar in the absence (black) and 
presence of 10, 30 and 100 µM diltiazem (green) in response to the 10 s 0mV voltage step 
from a holding potential of -80 mV. (B) Representative traces showing the direct application 
of 10, 30 and 100 μM diltiazem using a fast exchange system. hERG currents evoked at 0 
mV were exposed to diltiazem for 20 s to measure the onset of block; the drug was washed 
out between applications. (C) Exponential functions used to measure the timecourse of drug 
block were fit to the raw direct application data (D) Values for the time constants were 
measured by fitting exponential functions to the onset of block for 10 s depolarizing step, 
subtracted protocols (closed circles) and direct application of drug via fast perfusion (open 
circles). Data represents the mean ± SE of 4-5 cells. 
 
Figure 6: Drugs where onset of block is too slow to measure at 10 s. (A) shows a 
representative trace for 30 nM cisapride where the onset of block is too slow to measure 
accurately. The percentage block could be fit with a straight line. (B) Shows a comparison 
between time constants (τon) measured from 10, 20, 30 and 40 s duration 0mV voltage pulses. 
Data represents the mean ± the SD of 5 cells. (C) Representative traces of the 4 drugs with 
slow onset of block in response to 40 s 0mV voltage steps to 0mV from a holding potential of 
-80 mV at 15 s intervals. The control, the onset of block and subsequent sweeps are shown in 
black, dark colour and light colour, respectively. The time constants for all 4 slow drugs are 
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shown in (D). The data represents the mean ± SE and all data points are also shown. Closed 
circles indicate data obtained from 10s 0 mV voltage pulses and concentrations where the 
onset of block was too slow to measure are indicated by *. 
 
Figure 7: Drug trapping. (A) Drug trapping was calculated from the percentage block data of 
the 1st drug sweep (red) in comparison to the percentage block at the beginning of the 5th drug 
sweep (black). Exponential curves were fit to the data and extrapolated back to t = 0 to 
calculate the difference between the first (red) and last (black) drug sweeps (i) and expressed 
as a fraction of steady state block (ii). (B) Comparison of calculated trapping values for drugs 
with τon values > 500 ms. Data represents mean ± SE of 4 cells and the measurements are 
overlaid. 
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